Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06869785 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | PHASE3 | ACTIVE NOT_RECRUITING | 196 | — | — | Mar 13, 2025 | Mar 23, 2030 | May 12, 2026 | 65 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| Ofatumumab dose 1 | ACTIVE_COMPARATOR | Approved dosage |
| Ofatumumab dose 2 | EXPERIMENTAL | New dosage |
| Name | Type | Description |
|---|---|---|
| Ofatumumab approved dose | BIOLOGICAL | Approved dosage |
| Ofatumumab new dose | BIOLOGICAL | New dosage |
Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study. * Male or female study participants aged 18 to 60 years (inclusive) at screening. * Diagnosis of multiple sclerosis (MS) according to the 2017 Revised McDonald criteria (Thompson et al 2018). Relapsi...